Skip to main content

Table 1 Characteristics of docetaxel (DTX)- or curcumin (CUR)-loaded nanostructured lipid carriers (NLCs)

From: Synergistic co-administration of docetaxel and curcumin to chemoresistant cancer cells using PEGylated and RIPL peptide-conjugated nanostructured lipid carriers

 

pNLCs

P/R-NLCs

Empty

  

Size (nm)

161.4 ± 2.6

190.0 ± 4.8

PDI

0.277 ± 0.015

0.251 ± 0.011

ZP (mV)

–18.5 ± 0.9

–19.9 ± 0.8

DTX-loaded

  

Size (nm)

171.7 ± 6.4

192.4 ± 0.9

PDI

0.315 ± 0.024

0.249 ± 0.012

ZP (mV)

–16.7 ± 0.2

–17.2 ± 0.2

EE (%)

99.9 ± 0.01

99.2 ± 0.02

DL (%)

17.93 ± 0.04

17.96 ± 0.03

CUR-loaded

  

Size (nm)

161.0 ± 1.3

201.7 ± 1.2

PDI

0.254 ± 0.019

0.250 ± 0.014

ZP (mV)

–17.4 ± 0.5

–16.4 ± 0.3

EE (%)

99.9 ± 0.01

99.9 ± 0.01

DL (%)

10.31 ± 0.01

8.93 ± 0.01

  1. Data represent the mean ± SD (n = 3)
  2. DTX, docetaxel; CUR, curcumin; pNLCs, plain NLCs; P/R-NLCs, PEGylated and RIPL peptide-conjugated NLCs; PDI, polydispersity index; ZP, zeta potential; EE, encapsulation efficiency; DL, drug loading